Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Nuggehally R. Srinivas. (2016) Interspecies scaling of excretory amounts using allometry – retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. Xenobiotica 46:9, pages 784-792.
Read now
Read now
Gary David Bowers, Amanda Culp, Melinda J. Reese, Glenn Tabolt, Lee Moss, Stephen Piscitelli, Phuong Huynh, David Wagner, Susan L. Ford, Elizabeth P. Gould, Rennan Pan, Yu Lou, David A. Margolis & William R. Spreen. (2016) Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica 46:2, pages 147-162.
Read now
Read now
Articles from other publishers (19)
Lu Sun, Peng Nie, Li Luan, Piet Herdewijn & Ya-Tao Wang. (2023) Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update. European Journal of Medicinal Chemistry 261, pages 115847.
Crossref
Crossref
Simone Perazzolo, Zachary R. Stephen, Masa Eguchi, Xiaolin Xu, Rachele Delle Fratte, Ann C. Collier, Ann J. Melvin & Rodney J.Y. Ho. (2023) A novel formulation enabled transformation of 3-HIV drugs tenofovir–lamivudine–dolutegravir from short-acting to long-acting all-in-one injectable. AIDS 37:14, pages 2131-2136.
Crossref
Crossref
Yenju Chu, Abigail Wong, Haojie Chen, Liuhang Ji, Chaolong Qin, Wanshan Feng, Michael J. Stocks & Pavel Gershkovich. (2023) Development of lipophilic ester prodrugs of dolutegravir for intestinal lymphatic transport. European Journal of Pharmaceutics and Biopharmaceutics 191, pages 90-102.
Crossref
Crossref
Alicja Jakimiuk, Agnieszka Piechal, Alicja Wiercińska-Drapało, Alicja Nowaczyk & Dagmara Mirowska-Guzel. (2023) Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies. Pharmacological Reports.
Crossref
Crossref
Priya Dharshini K, Ramya Devi D, Banudevi S & Vedha Hari B. Narayanan. (2022) In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV. Scientific Reports 12:1.
Crossref
Crossref
Laura Labarthe, Thibaut Gelé, Hélène Gouget, Mariam-Sarah Benzemrane, Pauline Le Calvez, Nicolas Legrand, Olivier Lambotte, Roger Le Grand, Christine Bourgeois & Aurélie Barrail-Tran. (2022) Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice. Journal of Antimicrobial Chemotherapy 77:4, pages 1094-1101.
Crossref
Crossref
Jordan B. Joiner, Jasmine L. King, Roopali Shrivastava, Sarah Anne Howard, Mackenzie L. Cottrell, Angela D. M. Kashuba, Paul A. Dayton & Soumya Rahima Benhabbour. (2022) Effects of Injection Volume and Route of Administration on Dolutegravir In Situ Forming Implant Pharmacokinetics. Pharmaceutics 14:3, pages 615.
Crossref
Crossref
Thibaut Gelé, Hélène Gouget, Valérie Furlan, Pierre-Hadrien Becker, Anne-Marie Taburet, Olivier Lambotte & Aurélie Barrail-Tran. (2020) Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries. Antimicrobial Agents and Chemotherapy 64:11.
Crossref
Crossref
Usman Arshad, Henry Pertinez, Helen Box, Lee Tatham, Rajith K. R. Rajoli, Paul Curley, Megan Neary, Joanne Sharp, Neill J. Liptrott, Anthony Valentijn, Christopher David, Steve P. Rannard, Paul M. O’Neill, Ghaith Aljayyoussi, Shaun H. Pennington, Stephen A. Ward, Andrew Hill, David J. Back, Saye H. Khoo, Patrick G. Bray, Giancarlo A. Biagini & Andrew Owen. (2020) Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clinical Pharmacology & Therapeutics 108:4, pages 775-790.
Crossref
Crossref
Anna Halling Folkmar Andersen & Martin Tolstrup. (2020) The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection. Viruses 12:4, pages 412.
Crossref
Crossref
Dani Lakshman, Mohith Chegireddy, Geeta K. Hanegave, K. Navya Sree, Naveen Kumar, Shaila A. Lewis & Swapnil J. Dengale. (2020) Investigation of drug-polymer miscibility, biorelevant dissolution, and bioavailability improvement of Dolutegravir-polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer solid dispersions. European Journal of Pharmaceutical Sciences 142, pages 105137.
Crossref
Crossref
Maciej J. Zamek-Gliszczynski, Xuexiang Zhang, Jennypher Mudunuru, Yewei Du, Jian-Lu Chen, Kunal S. Taskar, Jane Huang, Yong Huang & Elizabeth H. Romach. (2019) Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways. Drug Metabolism and Disposition 47:8, pages 890-898.
Crossref
Crossref
Jackson Mukonzo, Eleni Aklillu, Vincent Marconi & Raymond F. Schinazi. (2019) Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. International Journal of Infectious Diseases 83, pages 98-101.
Crossref
Crossref
Junjie Zhu, Pengcheng Wang, Feng Li, Jie Lu, Amina I. Shehu, Wen Xie, Deborah McMahon & Xiaochao Ma. (2018) CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV integrase inhibitor. Biochemical Pharmacology 158, pages 174-184.
Crossref
Crossref
Smriti Kala, Birgit Watson, Jeremy Guijun Zhang, Eszter Papp, Monica Guzman Lenis, Michelle Dennehy, D. William Cameron, P. Richard Harrigan & Lena Serghides. (2018) Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens. Antiviral Research 159, pages 45-54.
Crossref
Crossref
Myoung Jin Ho, Dae Ro Lee, Sung Hyun Im, Jeong A Yoon, Chang Yong Shin, Hyun Jung Kim, Sun Woo Jang, Young Wook Choi, Young Taek Han & Myung Joo Kang. (2018) Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery. European Journal of Pharmaceutics and Biopharmaceutics 130, pages 143-151.
Crossref
Crossref
Mariana Cancian & Elgion L. S. Loreto. (2018) A Mos1 transposase in vivo assay to screen new HIV-1 integrase inhibitors. Genetica 146:2, pages 243-247.
Crossref
Crossref
Robin Kobbe, Stein Schalkwijk, Gabor Dunay, Johanna M. Eberhard, Ulf Schulze-Sturm, Bettina Hollwitz, Olaf Degen, Marga Teulen, Angela Colbers & David Burger. (2016) Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. AIDS 30:17, pages 2731-2733.
Crossref
Crossref
Michael T Eadon, Hongji Zhang, Todd C Skaar, Takashi Hato, Pierre C Dagher, Samir K Gupta & Zeruesenay Desta. (2015) A two-week regimen of high-dose integrase inhibitors does not cause nephrotoxicity in mice. Antiviral Chemistry and Chemotherapy 24:2, pages 72-76.
Crossref
Crossref